Puregraft and Suneva Medical partner in the US and Canada

08 01 2019

SAN DIEGOJan. 3, 2019 /PRNewswire/ — Suneva® MedicalInc., is proud to announce an exciting new partnership intended to shape the future of regenerative aesthetics. Building on the success of Bellafill, its flagship regenerative biostimulatory product and the longest lasting dermal filler on the market, Suneva Medical has signed a new partnership with Puregraft, LLC.

“The combination of our world class commercial organization and these unique and innovative Aesthetic products strategically positions us for long term growth as a leader in the regenerative aesthetic market,” says Preston Romm, CEO, Suneva Medical. “These new products will add significant breadth to Suneva’s product portfolio.”

Based in Solana Beach, California, Puregraft LLC is the world’s leading fat grafting company. In 15 minutes or less, the Puregraft products provide surgeons with purified fat for reinjection. Puregraft is devoted to developing fat based technology focused on the emerging regenerative aesthetics market. Suneva Medical has a distribution partnership with Bimini for certain markets on their proprietary Puregraft fat grafting system for use within the regenerative skin and body care industry and an exclusive relationship on their next generation technology scheduled to launch in early to mid-year 2019.

“Suneva Medical is a seamless connection for our Puregraft products and its next generation technology. We look forward to growing the relationship and working together to shape the global aesthetics market,” says Brad Conlan, CEO of Puregraft.

About Suneva Medical, Inc.
Suneva Medical is a privately‐held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the aesthetic markets. The innovative aesthetics leader markets Bellafill®, the only dermal filler on the market that is approved by the U.S. Food and Drug Administration for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years old. The company markets Bellafill® in the U.S., CanadaHong Kong, Korea and Mexico. For more information, visit www.sunevamedical.com.

Related Links